Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A

Antonietta Franco†, Xiawei Dang†, Emily K Walton, Joshua N Ho, Barbara Zablocka, Cindy Ly, Timothy M Miller, Robert H Baloh, Michael E Shy, Andrew S Yoo, Gerald W Dorn II

1Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States; 2Department of Cardiology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China; 3Department of Developmental Biology, Washington University School of Medicine, St Louis, United States; 4Center for Regenerative Medicine, Washington University School of Medicine, St. Louis, United States; 5Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland; 6Department of Neurology, Washington University School of Medicine, St Louis, United States; 7Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, United States; 8Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, United States

Abstract Charcot–Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal MFN2 mutation. In mice expressing human MFN2 T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting in vivo mitochondrial localization to neuromuscular junctional synapses. MiM111-treated MFN2 T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.

Introduction Charcot–Marie-Tooth disease (CMT) describes a family of genetically diverse and clinically heterogeneous peripheral neuropathies (Fridman et al., 2015). Type 2A CMT (CMT2A) is caused by mutations of the mitochondrial fusion protein, mitofusin 2 (MFN2) (Züchner et al., 2004), and is distinguished from other CMT subtypes by onset of neuromuscular signs in early childhood and progressive loss of neuromuscular coordination and strength in arms throughout the first two decades of life, thought to be the consequence of dying-back of long peripheral nerves (Fridman et al., 2015; Feely et al., 2011; Bombelli et al., 2014; Yaron and Schuldiner, 2016; Berciano et al., 2017). Because there are currently no disease-modifying treatments, CMT2A is managed with braces, wheelchairs, and social support.

Over 100 different dominant missense MFN2 mutations are implicated in CMT2A (Beręsewicz et al., 2018). MFN2 and related MFN1 are nuclear-encoded dynamin-family GTPases
located at the mitochondrial outer membrane-cytosol interface where they promote mitochondrial fusion essential to mitochondrial respiratory function and repair (Chan, 2012). Dominant inhibition by MFN2 mutants of mitochondrial fusion (Chen and Chan, 2006; Pareyson et al., 2015), mitophagy (Rizzo et al., 2016; Filadi et al., 2018), and/or neuronal mitochondrial transport (Pareyson et al., 2015; Baloh et al., 2007; Crunkhorn, 2018) are proposed to evoke neuronal degeneration in CMT2A.

Because CMT2A is an autosomal dominant genetic condition, gene editing could potentially correct causal MFN2 mutant alleles, but the large number of different causal CMT2A MFN2 mutations complicates an editing approach. Alternately, forced expression of normal mitofusins could oppose mutant MFN2 dysfunction, as demonstrated in a recent study in transgenic mice (Zhou et al., 2019). However, MFN gene therapy would be difficult to discontinue or reverse if postulated adverse effects of MFN overactivity are encountered (El Fissi et al., 2018). Here, we describe a therapeutic approach to CMT2A that is agnostic to MFN2 genotype and does not require genetic manipulation: intermittent or ‘burst’ activation of endogenous normal mitofusins. Pharmacological mitofusin activators improved mitochondrial morphology, fitness, and motility in human and mouse CMT2A neurons in vitro. Daily administration of a short acting mitofusin activator to mice with late stage CMT2A reversed neuromuscular dysfunction. Mechanistically, neuronal repair and regeneration were linked to enhanced mitochondrial transport to, and mitochondrial occupation within, axonal termini. Reversal of pre-existing CMT2A neuromuscular degeneration in vivo has not previously been achieved by any means, and provides a powerful rationale for advancing mitofusin activators to first in human trials.

Results

Genetically diverse CMT2A patient neurons exhibit similar mitochondrial phenotypes

One of the central features of CMT2A is the large number of different MFN2 mutations that provoke the syndrome. Common MFN2 GTPase and coiled-coiled domain mutations induce more severe and earlier onset disease, whereas rare carboxy terminal domain mutations confer later onset and milder disease (Feely et al., 2011; Stuppia et al., 2015). We compared mitochondrial phenotypes in cells from four CMT2A patients, two having MFN2 mutations within the canonical dynamin/Fzo-like GTPase domain (MFN2 T105M in the G1 motif and MFN2 R274W between the G4 and G5 motifs),
and two with mutations in the MFN2 coiled-coiled helix bundle core (MFN2 H361Y and R364W). (Figure 1—figure supplement 1). Donor patient characteristics are in Table 1.

To avoid loss of some CMT2A-associated mitochondrial phenotypes in iPSC-derived neurons (Rizzo et al., 2016; Saporta et al., 2015), we directly reprogrammed CMT2A patient fibroblasts into motor neurons via microRNA-mediated neuronal conversion (Figure 1b; Abernathy et al., 2017). Reprogramming efficiency was similar between CMT2A and control patient fibroblasts: >90% neurons (measured as β-III tubulin staining), and >85% motor neurons (measured as β-III tubulin, HB9/MNX1 co-staining) (Figure 1—figure supplement 2). Compared to neurons reprogrammed from individuals with no evident disease at the time of sampling and who had none of the tested MFN2 mutations by Sanger sequencing (‘normal’), all four CMT2A motor neuron lines exhibited fragmented mitochondria (decreased mitochondrial aspect ratio; length/width) that is a consequence of impaired fusion in this context Franco et al., 2016; accompanying mitochondrial depolarization reflected characteristic functional impairment (Figure 1c; Crowley et al., 2016). Moreover, all four CMT2A motor neuron lines exhibited abnormal mitochondrial transport through axons, with diminished proportion and velocity of motile mitochondria (Figure 1c). Mitochondrial fragmentation, respiratory dysfunction, and dysmotility observed in reprogrammed neurons are prototypical features of CMT2A (Baloh et al., 2007; Zhou et al., 2019; Verhoeven et al., 2006; Rocha et al., 2018).

Dominant inhibition of normal MFN1 and MFN2 by CMT2A MFN2 mutants produces an imbalance between mitochondrial fission and fusion that underlies mitochondrial pathology in CMT2A (Zhou et al., 2019). This dynamic imbalance can be reversed in transfected mouse cells and in vivo mouse models by forced overexpression of normal MFN1 or MFN2 (Zhou et al., 2019; Detmer and Chan, 2007). We posited that pharmacological activation of normal endogenous human MFN1 and MFN2 would also reverse mitochondrial abnormalities in CMT2A patient motor neurons. Chimera C is one of a new class of direct mitofusin activators that promotes conformational activation of MFN1 and MFN2, thereby stimulating endogenous mitofusins to improve mitochondrial dysmorphology and dysfunction (Rocha et al., 2018; Dang et al., 2020). Chimera C (100 nM, 48 hr) enhanced mitochondrial fusion (i.e. it increased aspect ratio) and improved respiratory function (i.e. it reversed mitochondrial depolarization) in cells lacking either MFN1 or MFN2, but had no effects in cells lacking both mitofusin targets (Figure 1—figure supplement 3). Chimera C (100 nM, 48 hr) also improved mitochondrial aspect ratio, depolarization, and motility in all four CMT2A patient motor neuron lines (Figure 1c).

**Neuron-specific expression of MFN2 T105M in mice recapitulates key features of human CMT2A**

Children with CMT2A are typically healthy during early years, but develop signs of neuromuscular dysfunction during the mid first decade of life. Neurogenic distal limb muscular atrophy is progressive until the end of the second decade, at which time the disease stabilizes; longevity is normal, but

| Diseases | Mutation | Age | Sex | Passage# | Source | Fibroblast ID |
|----------|----------|-----|-----|----------|--------|---------------|
| CMT2A    | MFN2 Thr105Met | 41  | F   | P4-P10   | Dr. Robert H. Baloh | - |
| CMT2A    | MFN2 Arg274Trp  | 23  | M   | P4-P10   | Dr. Barbara Zablocka | - |
| CMT2A    | MFN2 His361Tyr | 41  | M   | P4-P10   | Dr. Robert H. Baloh | - |
| CMT2A    | MFN2 His364Trp | 28  | F   | P6-P10   | Dr. Michael E. Shy | - |
| CMT1A    | PMP22 DUP  | 28  | F   | P4-P10   | Coriell Institute  | GM05167 |
| CTRL 1   | -        | 68  | F   | P3-P7    | NINDS        | ND34769 |
| CTRL 2   | -        | 71  | F   | P3-P7    | NINDS        | ND36320 |
| CTRL 3   | -        | 55  | F   | P3-P7    | NINDS        | ND29510 |
| CTRL 4   | -        | 66  | M   | P8-P10   | NINDS        | ND29178 |
| CTRL 5   | -        | 72  | M   | P3-P7    | NINDS        | ND34770 |
| CTRL 6   | -        | 55  | M   | P4-P10   | NINDS        | ND38530 |

Franco, Dang, et al. eLife 2020;9:e61119. DOI: https://doi.org/10.7554/eLife.61119
Figure 1. Mitochondrial abnormalities in reprogrammed CMT2A patient motor neurons and their improvement after mitofusin activation. (a) Model structure of MFN2 showing location of CMT2A patient mutations. (b) Schematic depiction of fibroblast reprogramming procedure to produce motor neurons. (c) Mitochondrial testing in reprogrammed motor neurons from four CMT2A patients with different MFN2 mutations and representative of Figure 1 continued on next page.
disability is permanent (Fridman et al., 2015; Feely et al., 2011). No mouse models of CMT2A recapitulate all of these key clinical features in the absence of confounding developmental phenotypes (Zhou et al., 2019; Detmer et al., 2008; Cartoni et al., 2010; Bannerman et al., 2016; Dorn, 2020). Therefore, a prerequisite for proof-of-concept testing of mitofusin activation in vivo was to generate a mouse CMT2A model having greater similarity to the human condition.

By combining Rosa26 <fs<sup>MFN2(T105M)</sup>] (Bannerman et al., 2016) and Mnx1-Cre (HB9) (Yang et al., 2001) alleles (Figure 2a) we drove human MFN2 T105M expression in mouse neurons (Figure 2b; CMT2A mouse). Neuromuscular functional integrity over time was assessed as the duration mice could walk on an elevated accelerated rotating cylinder without falling off (RotaRod latency). RotaRod latency of CMT2A mice was normal at 10 weeks of age, progressively declined thereafter, and stabilized beyond 30 weeks (Figure 2c). As in clinical CMT2A, axonal mitochondria of MFN2 T105M mice were fragmented with disorganized cristae (Sole et al., 2009; Figure 2d).

Neuroelectrophysiological testing of CMT2A patients characteristically reveals reduced compound muscle action potentials (CMAP) with normal nerve conduction velocities (Berciano et al., 2017; Harding and Thomas, 1980). Recapitulating this clinical finding, sciatic nerve-tibialis muscle CMAP amplitudes of 50-week-old MFN2 T105M mice were diminished with no change in signal latency, which reflects conduction velocity (Figure 2e). Tibialis myofiber atrophy and loss of large axons without demyelination in the MFN2 T105M mouse (vide infra) also mimicked clinical CMT2A (Verhoeven et al., 2006; Muglia et al., 2001; Neves and Kok, 2011).

To further evaluate the relevance of the MFN2 T105M mouse to human CMT2A, dorsal root ganglion (DRG) sensory neurons were isolated and placed in culture, the MFN2 T105M transgene induced with Adeno-Cre, and neurons assayed for the mitochondrial pathologies delineated in reprogrammed CMT2A patient motor neurons (vide supra). CMT2A-associated abnormalities in axon mitochondrial aspect ratio and transport (Figure 2f) and polarization status (Figure 2—figure supplement 1) were each mimicked in mouse CMT2A DRGs. As in reprogrammed human CMT2A motor neurons, mitofusin activation improved these abnormalities (Figure 2f and Figure 2—figure supplement 1, compare to Figure 1c).

**Burst mitofusin activation reverses neuromuscular dysfunction in CMT2A mice**

Collectively, the above results show that activating mitofusins can improve multiple mitochondrial abnormalities manifested by cultured human and mouse CMT2A neurons. To determine whether benefits of mitofusin activation in cultured neurons would translate to therapeutic effects on neuromuscular dysfunction in CMT2A we contemplated an in vivo trial in our CMT2A mouse. However, Chimera C is rapidly degraded by the liver and undergoes first-pass metabolism, making it impractical for in vivo studies (Dang et al., 2020). We therefore evaluated in vivo efficacy of mitofusin activation in CMT2A using MiM111, a structurally distinct compound having a mitofusin activation profile similar to Chimera C (Figure 1—figure supplement 3), but which is metabolically stable with good nervous system bioavailability (Dang et al., 2020). We hypothesized that intermittent or ‘burst’ mitofusin activation (a dosing schedule that reversed mitochondrial dysfunction for <12 hr each day) (Figure 3—figure supplement 1) would confer therapeutic benefits by cyclically enhancing mitochondrial fitness and transport, while minimizing the possibility of mitofusin toxicity that might occur with constant mitofusin activation (El Fissi et al., 2018; Meyer et al., 2017).

Based on a minimum effective MiM111 plasma concentration of 30 ng/ml (Dang et al., 2020) and a plasma t<sub>1/2</sub> of 2.3 hr with C<sub>max</sub> of 24,000 ng/ml after intramuscular administration of 30 mg/kg (Figure 3—figure supplement 1), we estimated that daily IM dosing would reverse mitochondrial
dysmotility in CMT2A mice for ~12 hr out of every 24 hr. Indeed, Figure 3—figure supplement 1 show that mitochondrial motility in sciatic nerve axons of MFN2 T105M mice was normalized 4 hr after a single intramuscular injection of MiM111 (30 mg/kg), declined by approximately half after 12 hr, and returned to CMT2A baseline after 24 hr.

If CMT2A neuron die-back is reversible then burst mitofusin activation should improve neuromuscular degeneration in MFN2 T105M mice who had progressed to the severe and stable CMT2A phenotype. To test this notion, 50-week-old MFN2 T105M mice and littermate controls were randomized to receive daily MiM111 or its vehicle. Researchers blind to genotype and treatment group performed Rotarod and neuro-electrophysiological testing after 4 and 8 weeks (Figure 3b).

Figure 2. Characteristics of a neuron-specific MFN2 T105M mouse model of CMT2A. (a) Schematic depiction Mfn2 “+T105M” expression strategy. (b) Immunoblot analysis of MFN2 expression in mouse sciatic nerves. (c) Serial RotaRod latency studies; CMT2A is green squares (n = 16), wild-type (WT) control is open circles (n = 6). (d) Electron micrographs of axonal mitochondrial from sciatic nerves (50 weeks). (e) Comparative neuro-electrophysiology study results of 50-week-old mice in panel c. (f) Response of CMT2A dorsal root ganglion neurons to mitofusin activation with Chimera C (100 nM, 48 hr). Top images are confocal micrographs of DRGs stained for mitochondria (red) and axons (green). Insets are higher power magnification to see mitochondrial morphology. Bottom images are kymographs showing mitochondrial (red) motility. Vertical columns are stationary mitochondria; lines transiting left to right or right to left are moving. P values are from t-test from 3 or four independent experiments.

The online version of this article includes the following figure supplement(s) for figure 2:

Figure supplement 1. Flow cytometric profiling of mitochondrial polarization status in mouse dorsal root ganglion (DRG) neurons.
The characteristic decreases in RotaRod latency and CMAP amplitude in MFN2 T105M mice (see Figure 2c and e) were reversed 4 weeks after MiM111 treatment and remained near normal after 8 weeks (Figure 3c and d); MiM111 had no effect on control mice (Figure 3—figure supplement 2).

Compared to sciatic nerves of vehicle-treated MFN2 T105M CMT2A mice, MiM111 treatment reduced axon damage (Figure 4a), increased axon diameter (Figure 4b), and increased staining for superior cervical ganglion 10 (SCG10; a marker of neuron regeneration) (Shin et al., 2014;
Figure 4. Mitofusin activation reverses histopathological findings in MFN2 T105M mice. (a) Toluidine blue stained sections of mouse mid tibial nerves. Arrows show blue-stained damaged axons in CMT2A mice. Quantitative group data for damaged axons and SCG10-regenerating axons (see Figure 4—figure supplement 1) are on the right. (b) Electron micrographs of mid-tibial nerve axons from CMT2A mouse study groups after 8 weeks of therapy. Note heterogeneity in axon size (top images; left graph) and mitochondrial abnormalities (bottom images, right graph). (c) Wheat germ agglutinin (WGA) labeled sections of tibialis anterior muscle and quantitative myocyte cross sectional area. (d) Confocal micrographs of neuromuscular junctions to show mitochondrial occupancy yellow organelles within red synapses (also see Figure 4—figure supplement 1). Each symbol represents results from one mouse. Data are means ± SD; p values are 1- or 2-way ANOVA. Figure 4 continued on next page.
Figure 4—figure supplement 1). These findings suggest that mitofusin activation reversed CMT2A-induced neuronal degeneration.

Skeletal myocytes of CMT2A mouse tibialis muscle innervated by the sciatic nerve were abnormally small (Figure 4c), reflecting neurogenic muscle atrophy (because the MFN2 T105M transgene is directed by neuron-specific HB9-Cre). In agreement with muscle atrophy being a secondary effect, skeletal myocyte mitochondria of CMT2A mice appeared structurally normal (Figure 4—figure supplement 1) compare to sciatic nerve axon mitochondria in Figures 2d and 4b. Therefore, normalization of tibialis myocyte diameter after mitofusin activation (Figure 4c) indicates restoration of neuromuscular integrity.

Collectively, the above findings provide indirect support for the idea that CMT2A mice suffer from distal neuron dieback that can be reversed by activating mitofusins. Reasoning that decreased neuromuscular junction density in CMT2A mice would constitute direct evidence for dieback, we quantified neuromuscular junctional synapses containing receptors for the neurotransmitter acetylcholine (AchR) in tibialis muscles of CMT2A mice. Compared to normal mice, CMT2A mice had ~50% fewer synaptic junctions/myocyte, which was reversed after mitofusin activator treatment (Figure 4—figure supplement 1). Strikingly, mitochondrial occupancy of vehicle-treated CMT2A neuromuscular synaptic junctions was also reduced by ~half compared to normal mice, and was normalized by MiM111 treatment (Figure 4d). Because mitochondrial transport can play a central role in neuron repair and regeneration (Sheng, 2017), the observation that MiM111 promoted mitochondrial localization within terminal neuromuscular synaptic junctions provided a plausible mechanistic link between mitofusin activation, mitochondrial motility, neuronal regrowth, and reversal of neuromuscular dysfunction in this preclinical CMT2A model.

Enhanced mitochondrial function in mitofusin-activated CMT2A DRGs leads to accelerated axon growth

Reversal of CMT2A-induced distal neuron die back implies neuronal regrowth. Indeed, sensory DRG neurons isolated from CMT2A mice and cultured in the presence of MiM111 (100 nM, 48 hr) exhibited not only enhanced mitochondrial fusion (increased aspect ratio) and transport (greater mitochondrial motility and velocity), but axon outgrowth (length and branching) (Figure 5). Similar effects were seen in CMT2A DRGs treated with Chimera C (100 nM, 48 hr) (Figure 5—figure supplement 1). Both MiM111 and Chimera C provoked mitochondrial redistribution to axonal termini of cultured CMT2A DRGs (Figure 5—figure supplement 1) recapitulating mitochondrial occupation of neuromuscular synapses after MiM111 treatment of CMT2A mice in vivo (see Figure 4d).

Comparing the mitochondrial motility, aspect ratio, and neuron growth responses at different times after mitofusin activation revealed significantly increased mitochondrial trafficking within 2 hr, whereas enhanced axon outgrowth was significant after 24 and 28 hr, and mitochondrial aspect ratio (i.e. fusion) was significant only after 48 hr (Figure 5—figure supplement 2). Given the established role for mitochondrial transport in neuronal repair (Sheng, 2017), this temporal sequence lends credence to the idea that accelerated neuron growth is a consequence of enhanced mitochondrial function and redistribution.

Mitofusin activation accelerates in vitro CMT2A axon regeneration after axotomy

DRG outgrowth measures in vitro regrowth of neuronal extensions that are amputated during the cell isolation trituration procedure. We considered that a more appropriate model of regrowth after dieback in CMT2A would test intact neurons lacking only the distal axons. Because CMT2A mouse neurons grow poorly in tissue culture in the absence of mitofusin activators (vide supra), this was not feasible using DRGs. Therefore, we seeded cortical neurons collected from MFN2 T105M allele mice in chambers separated from empty chambers by linear microchannels. In the absence of Cre-recombinase these ‘normal’ neurons grew axons through the microchannels that branched into the empty
Figure 5. Mitofusin activation reverses mitochondrial pathology and stimulates growth of CMT2A dorsal root ganglion neurons in vitro. (a) Confocal micrographs of CMT2A mouse DRGs cultured for 48 hr with MiM111 or its vehicle. Note greater neuronal process length and branching in MiM111-treated neuron. Exploded insets (right) show neuronal process termini. Mitochondria express mitoDS Red; neuronal processes stained for β-III tubulin are green. (b) Kymographs of mitochondrial motility in neuronal processes of live DRGs from studies shown in (a). Top panel is raw data. Bottom panels emphasize motile mitochondria with red and blue lines transiting left to right or right to left, respectively. (c-f) Quantitative group data demonstrating effect of MiM111 on CMT2A DRG mitochondrial aspect ratio (c), motility (d, e), neuronal process length and branching (e), and proportion of neuronal process termini containing mitochondria (f).

The online version of this article includes the following figure supplement(s) for figure 5:

Figure supplement 1. Mitofusin activation with Chimera C reverses mitochondrial pathology and stimulates growth of CMT2A dorsal root ganglion neurons in vitro.

Figure supplement 2. Time course studies of DRG mitochondria responses to mitofusin activation after aspiration axotomy.
chambers (Figure 6a). Adenoviral Cre was then used to activate the CMT2A MFN2 T105M transgene, followed after 48 hr by aspiration amputation of the branched axonal termini (Figure 6b and c). Mitochondrial motility and aspect ratio were measured 1 hr before and after axotomy; axon regrowth was measured 3 days after axotomy. The aspect ratio of mitochondria in the distal linear axons of normal and CMT2A neurons was unaffected either by axotomy or by MiM111 (Figure 6d, left panel). By contrast, and consistent with a previous study in normal neurons (Zhou et al., 2016), mitochondrial motility was reduced by axotomy (Figure 6d middle panels). Mitofusin activation with MiM111 after axotomy restored mitochondrial motility and neuronal outgrowth to pre-axotomy levels. Thus, the link between experimentally activating mitofusins, the subsequent increase in mitochondrial transport, and enhanced neuronal growth/repair was consistent for mouse CMT2A sciatic nerve axons in vivo, cultured CMT2A DRG neuron outgrowth, and cultured CMT2A cortical nerve regrowth after distal axotomy.

Discussion
These preclinical studies show that activating endogenous normal mitofusins can improve stable neuromuscular dysfunction caused by a CMT2A MFN2 mutant. Pharmacological mitofusin activation enhanced CMT2A neuron growth in vivo and in vitro by promoting mitochondrial fitness and

Figure 6. Mitofusin activation stimulates post-axotomy regrowth of CMT2A cortical neurons in vitro. (a) Schematic depiction of microfluidic platform. Yellow areas show proximal axon where mitochondrial motility was measured and distal axon where mitochondrial aspect ratio was measured. (b) Experimental design. DIV is days in vitro. Red arrows are times of pre- and immediate post-axotomy mitochondrial studies. (c) Representative images of CMT2A neuron terminal branches at different times relative to aspiration axotomy. (d) Quantitative group data demonstrating effect of MiM111 on CMT2A cortical neuron mitochondrial aspect ratio (left panel), motility (middle panels), and axon length (right panel).
transport, thereby reversing CMT2A-associated mitochondrial fragmentation, depolarization and stasis. We believe the key benefit that accrued from directly activating mitofusin-mediated mitochondrial fusion and motility was improved delivery of healthy mitochondria to neuromuscular junctions and axon growth buds. To our knowledge, this is the first report of any experimental intervention that fully reverses in vivo CMT2A phenotypes, demonstrating the feasibility of a clinically translatable disease-modifying therapeutic modality for this incurable condition.

Our studies integrated findings from multiple complementary experimental platforms. Motor neurons directly reprogrammed from CMT2A patient fibroblasts have not previously been described, and provided a platform in which effects of therapeutic interventions could be assessed on different patients’ mutations and individual genetic backgrounds using a disease-relevant cell type. Compared to iP cell-derived CMT2A neurons (Rizzo et al., 2016; Saporta et al., 2015), direct reprogramming more faithfully reproduced prototypical CMT2A mitochondrial phenotypes. Compared to the parental patient fibroblasts (Dang et al., in preparation), neurons permitted assessment of the CMT2A-associated mitochondrial motility disorders. While CMT2A has both sensory and motor neuropathy components, we reprogrammed specifically for motor neurons because motor components of this disease are the major source of patient disability.

All mouse disease models have advantages and limitations. Our CMT2A mouse model expresses human MFN2 T105M using a ‘motor neuron selective’ promoter (vide infra), and therefore does not exhibit sensory nerve involvement that is sometime manifested in clinical CMT2A. However, compared to other CMT2A mice, the current model more faithfully recapitulates CMT2A neuromuscular dysfunction that is the dominant cause of morbidity in the human condition (Fridman et al., 2015; Feely et al., 2011; Bombelli et al., 2014; Yaron and Schuldiner, 2016; Berciano et al., 2017). We previously used young adult mice carrying this combination of MFN2T105M and HB9-Cre alleles to evaluate effects of a topically applied prototype mitofusin activator on mitochondrial motility in sciatic nerve axons ex vivo (Rocha et al., 2018). It was not known if, with age, these mice would develop neuromuscular signs similar to clinical CMT2A. As shown here, motor function in these mice is normal at age 10 weeks, but declines until age 30 weeks whereupon it stabilized for at least another 20 weeks. This pattern is similar to the clinical course of CMT2A, in which apparently normal children typically manifest neuromuscular signs in the mid first decade of life, exhibit progressive loss of motor function in distal extremities over the next 10–15 years, and then stabilize. Moreover, the functional (neuroelectrophysiologival), histological, and ultrastructural features of axonal tissue in the mice were similar to the human condition. Together with the positive response to mitofusin activation in patient neurons, the improvement in neuromuscular function and cell/organelle pathology in MiM111-treated CMT2A mice supports the approach of mitofusin activation for the clinical disease.

Perhaps the most remarkable finding here is that mitofusin activation reversed the signs of CMT2A in mice with severe, stable disease. Every measured endpoint was improved, including gross neuromuscular function (RotaRod), electrophysiological metrics of neuromuscular integrity (CMAP), read-outs for axon degeneration, and multiple histological and ultrastructural assays of mitochondrial pathology in neurons. In vivo and in vitro results pointed to enhanced CMT2A neuron repair and regrowth as a central reason for phenotype reversal. Because it is not possible to functionally dissociate mitofusin-mediated increases in mitochondrial fusion and motility, it is unclear if one or the other of these responses preferentially underlies the neuroregenerative effects of mitofusin activation. However, it seems reasonable to postulate that mitochondrial delivery to distal neurons has greatest importance in the long peripheral nerves innervating hands, forearms, feet, and forelegs, i.e. those areas most impacted in CMT2A (Fridman et al., 2015; Feely et al., 2011; Bombelli et al., 2014; Yaron and Schuldiner, 2016; Berciano et al., 2017). In agreement with this notion, we observed a positive correlation between mitochondrial delivery to or occupancy of axonal termini and CMT2A neuron growth in vivo and in vitro.

As introduced above, damaging MFN2 mutations are a straightforward cause of CMT2A, but MFN2 multifunctionality complicates delineating the underlying cellular pathology (Filadi et al., 2018; Dorn, 2020). For this reason, the specific functional benefits accruing from mitofusin activation in CMT2A cannot unambiguously be defined. Mitochondrial fusion and motility are impaired in CMT2A (Chen and Chan, 2006) and allosteric mitofusin activation corrects both of these parameters (Franco et al., 2016; Rocha et al., 2018; Dang et al., 2020). Mitochondrial respiratory dysfunction, measured here as loss of inner membrane polarization, is a consequence of diminished fusion-
mediated homeostatic repair (Chen and Chan, 2006), and its improvement can therefore also be explained by enhanced fusogenicity. MFN2 has a role in mitophagic mitochondrial quality and quantity control (Chen and Dorn, 2013; Gong et al., 2015), and allosteric mitofusin activation suppressed the increase in autophagy/mitophagy induced by CMT2A mutant MFN2 T105M in cultured cells (Rocha et al., 2018). Finally, MFN2 can mediate physical interactions and calcium signaling between mitochondria and endoplasmic reticulum that may also have a role in CMT2A (Larrea et al., 2019), but effects of mitofusin activation on mitochondria- reticular interactions have not been described.

Here, we studied two structurally distinct but functionally similar allosteric mitofusin activators, a new class of drug that is the first to directly enhance mitochondrial fusion and transport. Although the prototype compounds were found not to be ‘druggable’, a new generation of mitofusin activators have addressed pharmaceutical limitations of the initial chemical series (Dang et al., 2020). As described previously (Rocha et al., 2018; Dang et al., 2020), mitofusin activators have minimal effects in normal cells, likely because increasing the probability that mitofusins are in their open/‘active’ conformation is a subtle intervention that can be readily compensated for in the absence of a pre-existing imbalance between mitochondrial fusion and fission. The current in vivo studies used a short-acting compound administered once daily to evaluate the effects of intermittent, or burst, mitofusin activation on CMT2A neuromuscular dysfunction. We considered that continuous long-term activation of mitochondrial fusion and transport might possibly be deleterious (El Fissi et al., 2018) (although it is worth noting that adverse effects of MFN1 and MFN2 overexpression in transgenic mice have not been reported). Moreover, we reasoned that the problem underlying CMT2A is the cumulative effects of long-term mitochondrial stasis and dysfunction on mitochondrial fitness and neuromuscular integrity. This scenario can explain why CMT2A progresses over many years in people and many weeks in mice. Our aim with burst activation was to turn back the disease clock through daily re-setting of mitochondrial function. By intermittently mobilizing healthy mitochondria to distal areas of physiological need, and simultaneously removing senescent or impaired mitochondria, neuron repair, renewal, and neuromuscular signaling were improved.

A mouse is not a man and human neuroregenerative capacity declines with age (Mattson and Magnus, 2006). For this reason we do not expect that mitofusin activation can fully reverse CMT2A phenotypes in older human patients with long-term stable disease. Nevertheless, the current results suggest that pharmacological mitofusin activation could offer the first disease-altering therapy for younger CMT2A patients. An intriguing possibility is that mitofusin activation may also have a therapeutic role in some of the many other neurodegenerative conditions not directly caused by mitofusin defects wherein mitochondrial fusion or transport are defective (Dang et al., in preparation; Knott et al., 2008; Burté et al., 2015).

**Materials and methods**

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Gene Mus musculus                 | Mfn-2       | NCBI Gene           | Gene ID: 170731 | MFN2 ENSMUSG0000029020 |
| Gene (Human)                      | MFN-2       | NCBI Gene           | Gene ID: 9927  | MFN2 ENSG00000116688 |
| Genetic reagent (M. musculus)     | Rosa-STOP-mMFN Thr105Met (T105M) mice | (C57BL/6 Gt(ROSA) 26 Sortm1 (CAG MFN2*T105M Dpel) | The Jackson Laboratory: 025322 | C57Bl/6 |
| Genetic reagent M. musculus       | HB9-Cre mice | (B6.129S1-Mnx1tm4 (cre)TmJ/J) | The Jackson Laboratory: 006600 | C57Bl/6 |

*Continued on next page*
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Genetic reagent *M. musculus*     | C57BL/6J mice | C57BL/6 | The Jackson Laboratory : 000664 | C57BL/6 |
| Mfn2 null *M. musculus*           | Mfn2 null MEFs | ATCC | CRL-2994 | Murine embryonic fibroblasts |
| Mfn1/Mfn2 null *M. musculus*      | Mfn1 and Mfn2 double knock out MEFs | ATCC | CRL-2993 | Murine embryonic fibroblasts |
| Mfn1 null *M. musculus*           | Mfn1 null MEFs | ATCC | CRL-2992 | Murine embryonic fibroblasts |
| Cell line (**H. sapiens**)        | Dermal fibroblast (MFN2 T105M) | Dr. Robert H. Baloh (Cedars Sinai) | Female |
| Cell line (**H. sapiens**)        | Dermal fibroblast (MFN2 H361Y) | Dr. Robert H. Baloh (Cedars Sinai) | Male |
| Cell line (**H. sapiens**)        | Dermal fibroblast (MFN2 R274W) | Dr. Barbara Zablocka (Mossakowski Med Res Ctr) | PMID:28076385 | Male |
| Cell line (**H. sapiens**)        | Dermal fibroblast (MFN2 R364W) | Dr. Michael E. Shy (University of Iowa) | Female |
| Cell line (**H. sapiens**)        | Dermal fibroblast (Normal) | NINDS | ND34769 | Female |
| Cell line (**H. sapiens**)        | Dermal fibroblast (Normal) | NINDS | ND36320 | Female |
| Cell line (**H. sapiens**)        | Dermal fibroblast (Normal) | NINDS | ND29510 | Female |
| Transfected construct (Human Adenovirus Type5 (dE1/E3)) | Adenovirus β-galactosidase | Vector Biolabs | Cat#: 1080 |
| Transfected construct (Human Adenovirus Type5 (dE1/E3)) | Adenovirus Mito-Ds-Red2 | Signagen | Cat#: 12259 |
| Transfected construct (Human Adenovirus Type5 (dE1/E3)) | Adenovirus Cre-recombinase | Vector Biolabs | Cat#: 1794 |
| Recombinant DNA reagent            | rTA-N144 (plasmid) | Addgene | Cat#: 66810 | Lentiviral construct to transfect and express the plasmid |
| Recombinant DNA reagent            | pTight-9-124-BclxL (plasmid) | Addgene | Cat#: 60857 | Lentiviral construct to transfect and express the plasmid |
| Recombinant DNA reagent            | LHX3-N174 and ISL1-N174 (plasmid) | PMID:28886366 | Lentiviral construct to transfect and express the plasmid |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Antibody                          | Anti-Mfn-2 (Mouse monoclonal) | AbCAM | Cat#: ab56889 | (1:1000) |
| Antibody                          | Anti-COX-IV (Rabbit polyclonal) | AbCAM | Cat#: ab16056 | (1:1000) |
| Antibody                          | Anti-Stathmin-2 (Rabbit polyclonal) | Novus Biologicals | Cat#: NBP1-49461 | (1:1000) |
| Antibody                          | Anti-GAPDH (Mouse monoclonal) | AbCAM | Cat#: ab8245 | (1:3000) |
| Antibody                          | Anti-FSP-1 (Rabbit polyclonal) | Novus Biologicals | Cat#: NBP1-49461 | (1:400) |
| Antibody                          | Anti-MNX1 (Mouse monoclonal) | DSHB | Cat#: 81.5C10 | (2 µg/ml) |
| Antibody                          | Anti-β-tubulin III (Mouse monoclonal) | Biolegend | Cat#: 801201 | (1:200) |
| Antibody                          | Alexa-Fluor 488 (Goat anti-mouse) | ThermoFisher | Cat#: A11029 | (1:400) |
| Antibody                          | Alexa-Fluor 488 (Goat anti-rabbit) | ThermoFisher | Cat#: A11008 | (1:400) |
| Antibody                          | (Goat anti-rabbit IgG) | ThermoFisher | Cat#: 31460 | (1:3000) |
| Antibody                          | Alexa-Fluor 594 (Goat anti-rabbit) | ThermoFisher | Cat#: A32740 | (1:400) |
| Antibody                          | (Peroxidase-conjugated anti-mouse IgG) | Cell Signaling | Cat#: 70765 | (1:3000) |
| Antibody                          | (α-Bungarotoxin Alexa flour 594) | ThermoFisher | Cat#: B12423 | (0.5 µg/ml) |
| Sequence-based reagent            | HB9CRE Fw | The Jackson Laboratory | 006600 | CTAGGCCACAGAATTGAAGATCT |
| Sequence-based reagent            | HB9CRE Rv | The Jackson Laboratory | 006600 | GTAGGTGGAAAATCTAGCATCATCC |
| Sequence-based reagent            | HB9CRE TG Fw | The Jackson Laboratory | 006600 | GCGGTCTGGCAGTTAAAAACTATC |
| Sequence-based reagent            | HB9CRE TG Rv | The Jackson Laboratory | 006600 | GTAAACACAGAGTGCTGTCACCT |
| Sequence-based reagent            | Mfn2 T105M M Fw | The Jackson Laboratory | 025322 | GACCCCGTTCACACACAAGA |
| Sequence-based reagent            | Mfn2 T105M M Rv | The Jackson Laboratory | 025322 | AACCTTGTCCAGAGCATGG |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Sequence-based reagent            | Mfn2 T105M Wt Fw | The Jackson Laboratory | 025322 | AAGGGAGCTGC AGTGGAGTA |
| Sequence-based reagent            | Mfn2 T105M Wt Rv | The Jackson Laboratory | 025322 | CCGAAAATCT GTGGGAAGTC |
| Sequence-based reagent            | MFN2 T105M Fw | This paper | PCR primers for cell line mutation validation | TTGCACCTGAA TAGGGCTTTG |
| Sequence-based reagent            | MFN2 T105M Rv | This paper | PCR primers for cell line mutation validation | CATTCCACCTC CACAGGGGTC |
| Sequence-based reagent            | MFN2 R274W Fw | This paper | PCR primers for cell line mutation validation | CGTGTTAGGGTG TCTACAAGAAGC |
| Sequence-based reagent            | MFN2 R274W Rv | This paper | PCR primers for cell line mutation validation | CTGGTGAGG GCTGATGAAAT |
| Sequence-based reagent            | MFN2 H361Y and R364W Fw | This paper | PCR primers for cell line mutation validation | CCTGGCAGTGA AAACCAAGAG |
| Sequence-based reagent            | MFN2 H361Y and R364W Rv | This paper | PCR primers for cell line mutation validation | AAGGCGTGCTG CCTAACAGGCC |
| Chemical compound, drug           | Trans-MiM111 | Mitochondria in Motion, Inc | Cpd 13b in PMID:32506913 | |
| Chemical compound, drug           | Chimera C | Paraza Pharma | Cpd 2 in PMID:32506913 | |
| Chemical compound, drug           | Papain | Sigma | Cat#: P4762 | |
| Chemical compound, drug           | Laminin | Sigma | Cat#: L2020 | |
| Chemical compound, drug           | Poly-d-Lysine | Sigma | Cat#: P7886 | |
| Chemical compound, drug           | Poly-ornithine | Sigma-Aldrich | Cat#: P4957 | |
| Chemical compound, drug           | Fibronectin | Sigma-Aldrich | Cat#: F4759 | |
| Chemical compound, drug           | Polybrene | Sigma-Aldrich | Cat#: H9268 | |
| Chemical compound, drug           | Doxycycline | Sigma-Aldrich | Cat#: D9891 | |
| Chemical compound, drug           | G418/Geneticin | Invitrogen | Cat#: 10131-035 | |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|------------|------------------------|
| Chemical compound, drug           | Retinoic Acid | Sigma              | Cat#: R2625 |                        |
| Chemical compound, drug           | BDNF, NT-3, CNTF, GDNF | Peprotech          | Cat#: 450-02, Cat#: 450-03, Cat#: 450-13, Cat#: 450-10 |                        |
| Chemical compound, drug           | Dibutyryl cAMP | Sigma              | Cat#: D0627 |                        |
| Chemical compound, drug           | Valproic acid | Sigma              | Cat#: 676380 |                        |
| Chemical compound, drug           | Puromycin | Invitrogen          | Cat#: A11138-03 |                        |
| Chemical compound, drug           | Collagenase | Worthington Biochemical | Cat#: 41J12861 |                        |
| Chemical compound, drug           | (2-Hydroxypropyl)-β-cyclodextrin | Sigma | Cat#: 332607 |                        |
| Chemical compound, drug           | Carbonyl cyanide-p-trifluoromethoxypyridyl hydrazone | Sigma | Cat#: C2759 |                        |
| Chemical compound, drug           | B27 supplement | Gibco              | Cat#: 17504-044 |                        |
| Chemical compound, drug           | Insulin-transferrin-sodium selenite | Sigma | Cat#: 1884 |                        |
| Chemical compound, drug           | Glucose | Sigma              | Cat#: G5767 |                        |
| Chemical compound, drug           | L-glutamine | Gibco              | Cat#: 25030-149 |                        |
| Chemical compound, drug           | Goat serum | Jackson Immunoresearch | Cat#: 005-000121 |                        |
| Chemical compound, drug           | Glutaraldehyde | Electron Microscopy Science | Cat#: 16216 |                        |
| Chemical compound, drug           | MitoTracker Green | Thermo Fisher | Cat#: M7514 |                        |
| Chemical compound, drug           | Calcein AM | Thermo Fisher       | Cat#: C3100MP |                        |
| Chemical compound, drug           | Hoechst | Thermo Fisher       | Cat#: H3570 |                        |
| Chemical compound, drug           | MitoTracker Orange | Thermo Fisher | Cat#: M7510 |                        |

*Continued on next page*
Mouse lines

Rosa-STOP-mMFN Thr105Met (T105M) mice (C57BL/6 Gt(Rosa)26 Sortm1 (CAG-MFN2*T105M) Dple/J) from The Jackson Laboratory (Bar Harbor, Maine, USA; Stock No: 025322, RRID: MGI:_JAX:025322) were crossed to HB9-Cre mice (B6.129S1-Mnx1tm4(cre)Tmj/J) from The Jackson Laboratory (Stock No: 006600, RRID: MGI:_JAX:006600)) to generate neuron-targeted MFN2 T105M mice. HB9 is a motoneuron-specific promoter (Yang et al., 2001), but JAX data indicates that this HB9-Cre line also drives expression in some sensory DRG neurons (https://images.jax.org/webclient/img_detail/20564/). All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19–0910, Exp:12/16/2022.

Cell lines

Normal mouse embryonic fibroblasts (MEFs) were prepared by enzymatic dissociation from embryonic day E13.5–14.5 C57BL/6J mice (The Jackson Laboratory Cat:# 000664, RRID: IMSR_JAX:000664). Mfn1 null and Mfn2 null Mfn1/Mfn2 double null MEFs fibroblasts were purchased from American Type Culture Collection (ATCC Manassas, Virginia, USA) (CRL-2992, RRID: CVCL_L691 and CRL-2994, RRID: CVCL_L692 and CRL-2993, RRID: CVCL_L693 respectively). Human fibroblast: Dermal fibroblast (MFN2 T105M) and Dermal fibroblast (MFN2 H361Y) from Dr. Robert H. Baloh (Cedars Sinai), Dermal fibroblast (MFN2 R274W) from Dr. Barbara Zablocka (Mossakowski Med Res Ctr), Dermal fibroblast (Normal) from NINDS respectively: ND34769, (RRID: CVCL_EZ04, ND36320, RRID: CVCL_EZ16 and ND29510, RRID: CVCL_Y813).

Viral vectors

Adenovirus expressing human FLAG-hMFN2 -T105M was prepared at Vector Biolabs (Malvern, PA, USA). Adenovirii expressing β-galactosidase (Ad-CMV-β-Gal; #1080), and Ad-Cre (#1794) were purchased from Vector Biolabs. Adenovirus for Mito-Ds-Red2 came from Signagen (Cat:#SL1007744). Lentivirus packaging vectors: psPAX2 (Addgene, Cat#: 12260) pMD2.G (Addgene, Cat#: 12259), Lentiviral vectors with recombinant DNA: rTA-N144 (Addgene, Cat#: 66810) pTight-9–124-BclxL (Addgene, Cat#: 60857), human LHX3-N174 and human ISL1-N174 were packaged and used as described (Abernathy et al., 2017).

Antibodies

Mouse monoclonal anti-mitofusin 2 (Cat # ab56889 - 1:1000, RRID: AB_2142629), anti-COX-IV (Cat #ab16056 - 1:1000, RRID: AB_443304) and anti-GAPDH (Cat #ab8245 - 1:1000, RRID: AB_2107448).
DNA was extracted from 5 × 10^6 primary human fibroblasts using the DNeasy blood and tissue kit (Qiagen, Cat#: 69506) according to manufacturer’s protocol. PCR used Taq Plus Master Mix 2X (Cat#: BETAQR-L, Bulls eye). 50 ng of genomic DNA template, and the following primers:

(MFN2 T105M) - 5’- TTGCACTGAATAGGGCTTTG- 3’
5’- CATTCCACCTCCACAGGGGTG- 3’

(MFN2 R274W) - 5’- CGTGGTAGGTGTCTACAAGAAGC- 3’
5’- CTGGTGAGGGCTGATGAAAT- 3’

(MFN2 H361Y, R364W) - 5’- CCTGGCAGTGAAAACCAGAG- 3’
5’- AAGGCGTGTCCTAACTGCC- 3’.

PCR products were purified using PureLink Quick Gel Extraction Kit (Cat#: K21000-12, Invitrogen). Sanger sequencing of PCR products was performed at GENEWIZ.

Cultured cells

Direct reprogramming of human motor neurons from patient fibroblasts used the procedure as described (Abernathy et al., 2017). Reprogramming cocktail consisted of 1 ml concentrated lentivirus containing the reverse tetracycline-controlled transactivator (rtTA; Addgene, Cat# 66810), 1 ml virus containing pT-BclXL-9/9* (M.O.I. of 50) 48 hr prior to study. DRG neurons were distinguished from non-neuronal cells by staining with anti-β-III tubulin.
used to triturate the solution until no more tissue was visible. Cortical neurons were plated in microfluidic neuron XonaChip chambers as described below.

**Imaging**

Static confocal imaging of cultured neurons used triple-stained with MitoTracker Green (200 nM; Invitrogen, Thermo Fisher Scientific Cat:# M7514) to visualize mitochondria, tetramethylrhodamine ethyl ester (TMRE, 200 nM, Invitrogen Thermo Fisher Scientific Cat:# T-669) that labels mitochondria with normal polarization of the mitochondrial inner membrane, and Hoechst (10 μg/ml; Invitrogen, Thermo Fisher Scientific Cat:# H3570) that stains nuclei blue as described (Franco et al., 2016). Static live cell images were acquired on a Nikon Ti Confocal microscope using a 40x oil objective as described (Franco et al., 2016). Static live cell images were acquired on a Nikon Ti Confocal microscope using either a 60 × 1.3 NA oil-immersion objective or 10 × 0.3 NA dry objective, in Krebs-Henseleit buffer (138 NaCl, 3.7 mM KCL, 1.2 mM KH2PO4, 15 nM glucose, 20 mM HEPES pH: 7.2–7.5, and 1 mM CaCl2): laser excitation was 488 nm with emission at 510 nm for MitoTracker Green and Ad-Mito GFP, 549 nm with emission at 590 nm for TMRE, and 306 nm with emission 405 nm for Hoechst and DAPI.

Axon branching analysis of CMT2A mouse DRGs was performed at various times after isolation and plating, as indicated. In some studies neurons were infected with Ad-mito-RFP to label mitochondria red. Cells were fixed and labeled with anti-β-tubulin III (1:200 in 10% goat serum in PBS) to identify neurons. Images were acquired using the 10x objective and excitation at 488 nm/emission 510 nm for Alexa-Flour 488 and 579 excitation/599 emission for mito-RFP. Sholl analysis of axonal branching used ImageJ (Schneider et al., 2012) and an open source plugin (https://imagej.net/Sholl_Analysis). Briefly, a starting radius was set to encompass the soma of β-tubulin III-positive DRG neurons and concentric circles established at 10 micron increments, to 40 microns. Numbers of axon and radii intersections were totaled for all circles to derive intersection number, which is a measure of axonal branching. Special attention was given to ensure that there was uniform staining along all parts of the DRG soma and axons so that the plugin was able to accurately assess the number of intersections accurately.

Video confocal studies of mitochondrial motility studies in neurons and sciatic nerves used time-lapse imaging (1 frame every 5 s) for 121 frames (10 min, sciatic nerve) or 180 frames (15 min, cortical neurons) at 37°C on a Nikon A1Rsi Confocal Microscope using a 40x oil objective as described (Rocha et al., 2018). Cultured neuron mitochondria were labeled with Adeno-mitoDsRed2 or Mito-Tracker Orange (200 nM, Invitrogen Thermo Fisher Scientific Cat:# M7510) excited at 561 nm, emission 585 nm. Sciatic nerve axon mitochondria were labeled with TMRE. Kymographs and quantitative data were generated using an Image-J plug-in.

In vitro microfluidic studies of axon growth used primary cortical neurons isolated from embryonic day 18.5 MFN2 T105M flox-stop mice. 50,000–90,000 suspended cells in 20 μl of Earle’s Minimal Essential Medium (MEM; #11090–081; Gibco) supplemented with 5% FBS (Gibco #16140–063), 5% horse serum (HS) (Gibco #26050–070), 400 μM L-glutamine (Gibco #25030–149), 50 units/ml each penicillin/streptomycin (Gibco #15070–063) and 0.3% glucose (Sigma G 5767) (5–5 media) was added to the left chambers of XonaChips with 450 μl of 5–5 medium supplemented with 0.5 μl insulin-transferrin-sodium selenite (Sigma I 1884) was added to each well and neurons cultured under standard conditions. After 24 hr the medium was changed to neurobasal medium (#21103–049; Gibco, Carlsbad, CA, USA), 1x B27 supplement (#17504–044, Gibco, Carlsbad, CA, USA), 50 units/ml each penicillin/streptomycin (#15070–063; Gibco, Carlsbad, CA, USA) and 400 μM L-glutamine (#25030–149; Gibco, Carlsbad, CA, USA) with feeding every 2 to 3 days until axotomy (DIV 12), and infected with adeno-Cre for 48 hr to induce MFN2 Thr105Met expression. Vacuum aspiration axotomy and post-axotomy regrowth analyses were performed as described (Zhou et al., 2016). Aspiration axotomy was followed by application of fresh neuron feeding medium containing MIM111 (100 nM) or its vehicle (Me2SO, 1:1,000). Cells were fixed in situ; axonal outgrowth and post-axotomy regrowth were analyzed by confocal analysis of β-III tubulin positive cells. The area of βIII-tubulin signals above the same threshold within a 1024 × 1024 image that covers all axon segments extending from microgrooves was measured using ImageJ (NIH) and reported as pixels density of axon segments extending from an average of all microgrooves.

Immunoblot analysis was performed on mouse sciatic nerve proteins size-separated on 10% SDS-PAGE gels (Biorad Cat# 456–1036) and transferred to 0.45 μM Polyvinylidene fluoride (PVDF).
membranes (GE-Amersham, Freiburg, Germany Cat# 10600023). Membranes were blocked with 5% non-fat milk for 30 min and incubated with primary antibody overnight at 4°C. Peroxidase-conjugated secondary antibodies and Chemiluminescence Substrate (Thermo Scientific #32132) were used for signal detection. Quantification of immunoreactive proteins was performed on a LI-COR Odyssey infrared detection system (Lincoln, NE, USA, version 1.0.17).

Flow cytometric analysis of mitochondrial electrochemical potential
Cultured neurons were stained in situ with TMRE (200 nM, Invitrogen Thermo Fisher Scientific Cat#: T-669) for 30 min at 37°C in 5% CO₂–95% air, washed twice in PBS, and released from culture substrates with 0.05% Trypsin-EDTA (Gibco, cat#: 1995647). After centrifugation, the DRG pellets were re-suspended in 200 μl of FACS buffer (PBS 1X, BSA 1X, 2 Mm EDTA). Flow cytometry of TMRE fluorescence was performed on a Gallios instrument (Beckman Coulter) and analyzed using FlowJo10 software. ~3500 events were acquired for each sample. Data are presented as Mean Fluorescence Intensity per experiment. In some studies, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 10 μM for 1 hr) (Sigma, Cat #C2759) was added as a positive control for mitochondrial depolarization.

Evaluation of neuromuscular phenotypes in CMT2A mice
Rotarod studies were performed on mice initially acclimated to the RotaRod (Ugo Basile, Gemonio, VA, Italy;# 47650) at a speed of 5 r.p.m. CMT2A mice underwent RotaRod evaluations weekly from 10 to 50 weeks for disease development, and 4 and 8 weeks after mitofusin activator therapy. The acceleration protocol increased from 5 to 40 r.p.m over 120 s and then maintained 40 r.p.m. indefinitely. Each mouse underwent five separate trials per testing event with 5 min rest between trials. Latency (time to falling off) was averaged for all trials.

Neuroelectrophysiologic recordings of tibialis/gastrocnemius compound muscle action potentials (CMAP) were performed with a Viasys Healthcare Nicolet Biomedical instrument (Middleton, WI, USA Cat#: OL060954) running Viking Quest version 11.2 software by an operator (A.F.) blinded to genotype and treatment group. Mice were anesthetized with isofluorane (4–5% induction, 1.5% maintenance), shaved, and the proximal sciatic nerves stimulated using a needle electrode (Natus, Mundelein, IL, USA Cat#: F-E2-48) with 3.9 mV pulses of 0.002 ms duration. Ring electrodes (Natus, Mundelein, IL, USA Cat#: 291965) were positioned at the mid forelimb at the belly of the tibialis anterior and gastrocnemius muscles to record CMAP. Optimal stimulating electrode position was determined as that giving the greatest CMAP amplitude; 3–4 independent events were recorded and averaged.

Evaluation of CMT2A mouse responses to MiM111
Twelve 50-week-old CMT2A mice (HB9-Cre + MFN2 Thr105Met flox-stop) and six littermate controls were randomized and blinded to daily intramuscular treatment with MiM111 or vehicle for 8 weeks: under sterile conditions18.75 mg/ml (64.8 mM) MiM 111 was dissolved in 10% Me₂SO/90% (2-hydroxypropyl)-β-cyclodextrin (HP-BCD; Sigma, Cat: #332607), sterile-filtered (0.22 μm PVDF, #SLGV033RS, Millipore, Cork, Ireland), and drug- or vehicle-containing syringes were assigned to individual mice by XD using a randomization table. Daily intramuscular injections (biceps femoris muscle, alternating left and right every other day) were performed by AF, who was blinded to both mouse genotype and drug treatment group. Rotarod and neurophysiological testing were performed before, and 4 and 8 weeks after initiation of therapy. Mice were terminated by anesthesia overdose after 8 weeks for tissue studies. Sciatic and mid tibial nerves were dissected from both legs of all mice. For histology and immunohistology the left leg nerves or muscles were fixed in PFA for 2 hr, transferred to 30% sucrose/PBS overnight at 4°C, and embedded in optimal cutting temperature (OCT, Tissue-TEK Cat: 4583) medium for storage at ~80°C. Immunostaining with anti-Superior Cervical Ganglion 10 (SCG10) or wheat germ agglutinin labeling (WGA, Cat:#W834, Invitrogen) was performed on 10 μm cryostat sections briefly (5 min) brought to room temperature and then re-cooled to ~20°C for 30 min. RGB rightness of the representative images was increased uniformly for presentation purposes.
Mitochondrial occupancy in neuromuscular synaptic junctions was assessed in 10 μm cryostat tibialis muscle sections using anti-COXIV (1:200 in 10% goat serum) to label mitochondria and anti-acetylcholine receptor with α-Bungarotoxin to label neuronal synapses.

Transmission electron microscopy and toluidine blue staining used standard techniques (Zhou et al., 2019).

Data presentation and statistical analyses
Data are reported as means ± SD. Two-group comparisons used Student’s t-test; multiple group comparisons used one-way ANOVA, and time-course by treatment group or genotype by treatment group comparisons used two-way ANOVA, with Tukey’s post-hoc test for individual statistical comparisons. p<0.05 was considered significant.

Mouse treatment was randomized according to a random integer table (even or odd) and performed by investigators blind to both genotype and treatment status. Post terminal analysis of tissue and cell phenotypes was performed blindly.

Samples size estimation: Using two-sample t-test based on the preliminary data where the coefficients of variation (CV) at 50 weeks were 10% and 15% for rotarod latency and CMAP amplitude, respectively, the study was initially designed to have a sample size of 15 mice/group, providing 80% power at 1-sided α = 0.05. Because the therapeutic response for targeted differences was greater than anticipated, the study was completed with a reduced sample size of n = 6/group.

Acknowledgements
We gratefully acknowledge helpful discussions with Drs. P Needleman, PV Halushka, and D Mochly-Rosen, the specialized assistance of L Zhang, and C Cantoni for flow cytometry analysis. Funding: Supported by NIH R35HL135736, R41NS113642, R41NS115184, Research Grant 628906 from the Muscular Dystrophy Association (GWD), and a McDonnell Center for Cellular and Molecular Neurobiology Postdoctoral Fellowship (AF). GWD is the Philip and Sima K Needleman-endowed Professor and a Scholar-Innovator awardee of the Harrington Discovery Institute, Videoconfocal and electron microscopy studies were performed at the Washington University Center for Cellular Imaging (WUCCI) supported by the Washington University School of Medicine, the Children’s Discovery Institute of Washington University (CDI-COREs 2015–515 and 2019–813) and the Foundation for Barnes-Jewish Hospital (3770 and 4672). Competing interests: GWD is an inventor on patent applications PCT/US18/028514 submitted by Washington University and PCT/US19/46356 submitted by Mitochondria Emotion, Inc that cover the use of small molecule mitofusin agonists to treat chronic neurodegenerative diseases, and is a founder of Mitochondria in Motion, Inc, a Saint Louis based biotech R and D company focused on enhancing mitochondrial trafficking and fitness in neurodegenerative diseases. The other authors declare no competing interests. Data and materials availability: All data are available in the manuscript or the supplementary material. Studies using MiM111 were performed under terms of an MTA between Mitochondria in Motion, Inc and Washington University.

Additional information

Competing interests
Gerald W Dorn II: GWD is an inventor on patent applications PCT/US18/028514 submitted by Washington University and PCT/US19/46356 submitted by Mitochondria Emotion, Inc that cover the use of small molecule mitofusin agonists to treat chronic neurodegenerative diseases, and is a founder of Mitochondria in Motion, Inc, a Saint Louis based biotech R and D company focused on enhancing mitochondrial trafficking and fitness in neurodegenerative diseases. The other authors declare that no competing interests exist.
Author contributions
Antonietta Franco, Resources, Data curation, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing; Xiawei Dang, Resources, Data curation, Formal analysis, Validation, Methodology, Writing - original draft, Writing - review and editing; Emily K Walton, Resources, Methodology; Joshua N Ho, Resources, Validation, Methodology, Special expertise and data interpretation; Barbara Zablocka, Michael E Shy, Resources, Provided essential reagents and intellectual input; Cindy Ly, Validation, Methodology, Provided special expertise and data interpretation; Timothy M Miller, Validation, Methodology, Provided essential reagents and intellectual input; Robert H Baloh, Resources, Validation, Methodology, Provided essential reagents and intellectual input; Gerald W Dorn II, Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing

Author ORCIDs
Antonietta Franco http://orcid.org/0000-0002-5487-1800
Xiawei Dang http://orcid.org/0000-0002-0343-7107
Andrew S Yoo http://orcid.org/0000-0002-0304-3247
Gerald W Dorn II https://orcid.org/0000-0002-8995-1624

Ethics
Animal experimentation: All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19-0910, Exp:12/16/2022 (Gerald Dorn, PI).

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.61119.sa1
Author response https://doi.org/10.7554/eLife.61119.sa2

Additional files
Supplementary files
• Transparent reporting form

Data availability
All data generated or analyzed during this study are included in the manuscript.

References
Abernathy DG, Kim WK, McCoy MJ, Lake AM, Ouwenga R, Lee SW, Xing X, Li D, Lee HJ, Heuckeroth RO, Dougherty JD, Wang T, Yoo AS. 2017. MicroRNAs induce a permissive chromatin environment that enables
neuronal Subtype-Specific reprogramming of adult human fibroblasts. Cell Stem Cell 21:332–348. DOI: https://doi.org/10.1016/j.stem.2017.08.002, PMID: 2888636

Balogh RH, Schmidt RE, Pestronk A, Milbrandt J. 2007. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. Journal of Neuroscience 27:422–430. DOI: https://doi.org/10.1523/JNEUROSCI.4799-06.2007, PMID: 17215403

Banxner P, Burns T, Xu J, Miers L, Pleasure O. 2016. Mice hemizygous for a pathogenic Mitofusin-2 allele exhibit hind limb/foot gait deficits and phenotypic perturbations in nerve and muscle. PLOS ONE 11: e0167573. DOI: https://doi.org/10.1371/journal.pone.0167573, PMID: 27907123

Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, Gazulla J, Martinez-Tames M, Infante J, Jordanova A. 2017. Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. Journal of Neurology 264:1655–1677. DOI: https://doi.org/10.1007/s00415-017-8474-3, PMID: 28364294

Bergesewicz M, Charzewski Ł, Kryśko KA, Ko查ñski A, Zabłocka B. 2018. Molecular modelling of mitofusin 2 for a prediction for Charcot-Marie-Tooth 2A clinical severity. Scientific Reports 8:16900. DOI: https://doi.org/10.1038/s41598-018-35133-9, PMID: 30442897

Bomelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, Amati-Bonneau P, Latour P, Vignal O, Cazeneuve C, Brice A, Leguern E. 2014. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurology 71:1036–1042. DOI: https://doi.org/10.1001/jamaneurol.2014.629, PMID: 24957169

Burté F, Carelli V, Chinnery PF, Wu-Wai-Man P. 2015. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nature Reviews Neurology 11:11–24. DOI: https://doi.org/10.1038/nrneurol.2014.228, PMID: 25486875

Cartoni R, Arnaud E, Méard JJ, Poirot O, Couvoisier DS, Chrast R, Martinou JC. 2010. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain 133:1460–1469. DOI: https://doi.org/10.1093/brain/awp082, PMID: 20418531

Chan DC. 2012. Fusion and fission: interlinked processes critical for mitochondrial health. Annual Review of Genetics 46:265–287. DOI: https://doi.org/10.1146/annurev-genet-110410-132529, PMID: 22934639

Chen H, Chan DC. 2006. Critical dependence of neurons on mitochondrial dynamics. Current Opinion in Cell Biology 18:453–459. DOI: https://doi.org/10.1016/j.ceb.2006.06.004, PMID: 16781135

Chen Y, Dorn GW. 2013. PINK1-phosphorylated mitofusin 2 is a parkin receptor for culling damaged mitochondria. Science 340:471–475. DOI: https://doi.org/10.1126/science.1230131, PMID: 23620051

Crowley LC, Christensen ME, Waterhouse NJ. 2016. Measuring mitochondrial transmembrane potential by TMRE staining. Cold Spring Harbor Protocols 2016:pdb.prot087361. DOI: https://doi.org/10.1101/pdb.prot087361

Crumkorn S. 2018. Neurodegenerative disorders: rescuing mitochondrial motility. Nature Reviews. Drug Discovery 17:391. DOI: https://doi.org/10.1038/nrd.2018.76, PMID: 29739117

Dang X, Zhang L, Franco A, Li J, Rocha AG, Devanathan S, Dolle RE, Bernstein PR, Dorn GW. 2020. Discovery of 6-Phenylhexanamide derivatives as potent stereoselective mitofusin activators for the treatment of mitochondrial diseases. Journal of Medicinal Chemistry 63:7033–7051. DOI: https://doi.org/10.1021/acs.jmedchem.0c00366, PMID: 32506913

Detmer SA, Vande Velde C, Cleveland DW, Chan DC. 2008. Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A. Human Molecular Genetics 17:367–375. DOI: https://doi.org/10.1093/hmg/ddm314, PMID: 17959936

Detmer SA, Chan DC. 2007. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by severe phenotypes in most patients with CMT2A disease. Journal of Cell Biology 176:405–414. DOI: https://doi.org/10.1083/jcb.200611080, PMID: 17296794

Dorn GW. 2020. Mitofusin 2 dysfunction and disease in mice and men. Frontiers in Physiology 11:782. DOI: https://doi.org/10.3389/fphys.2020.00782, PMID: 32733278

El Fissi N, Rojo M, Aouane A, Karatas E, Polliackova G, David C, Royet J, Rival T. 2018. Mitofusin gain and loss of function drive pathogenesis in Drosophila models of CMT2A neuropathy. EMBO Reports 19:e45241. DOI: https://doi.org/10.15252/embr.201745241, PMID: 29989854

Feely SM, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, Reilly MM, Shy ME. 2011. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 76:1690–1696. DOI: https://doi.org/10.1212/WNL.0b013e31821a441e, PMID: 21508331

Filadi R, Pendin D, Pizzo P. 2018. Mitofusin 2 from functions to diseases. Cell Death & Disease 9:330. DOI: https://doi.org/10.1038/s41419-017-0023-6, PMID: 29491355

Franco A, Kittis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, Kris PM, Mennerick S, Dorn GW, Dorn GW. 2016. Correcting mitochondrial fusion by manipulating mitofusin conformations. Nature 540:74–79. DOI: https://doi.org/10.1038/nature20156, PMID: 2775718

Fridman V, Bundy B, Reilly MM, Pareyson D, Bacon C, Burns J, Day J, Feely S, Finkel RS, Grider T, Kirk CA, Herrmann DN, Laurá M, Li J, Lloyd T, Sumner CJ, Muntoni F, Piscosquito G, Ramachandran S, Shy R, et al. 2015. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. Journal of Neurology, Neurosurgery & Psychiatry 86:873–878. DOI: https://doi.org/10.1136/jnnp-2014-308826
Franco, Dang, et al. eLife 2020;9:e61119. DOI: https://doi.org/10.7554/eLife.61119
Zhou Y, Carmona S, Muhammad AKMG, Bell S, Landeros J, Vazquez M, Ho R, Franco A, Lu B, Dorn GW, Wang S, Lutz CM, Baloh RH. 2019. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model. Journal of Clinical Investigation 129:1756–1771. DOI: https://doi.org/10.1172/JCI124194

Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, N elis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, et al. 2004. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genetics 36:449–451. DOI: https://doi.org/10.1038/ng1341, PMID: 15064763